INVO Fertility, Inc. (NAYA)
NASDAQ: NAYA · Real-Time Price · USD
2.200
+0.170 (8.37%)
At close: Apr 25, 2025, 4:00 PM
2.430
+0.230 (10.45%)
After-hours: Apr 25, 2025, 7:44 PM EDT

Company Description

INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases.

The company operates in two divisions, NAYA Women’s Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases.

The company also offers INVOcell, a a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body.

The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025.

INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.

INVO Fertility, Inc.
INVO Fertility logo
Country United States
Founded 2007
Industry Medical Devices
Sector Healthcare
CEO Steven Shum

Contact Details

Address:
5582 Broadcast Court
Sarasota, Florida 34240
United States
Phone 978-878-9505
Website nayabiosciences.com

Stock Details

Ticker Symbol NAYA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001417926
ISIN Number US44984F4019
Employer ID 20-4036208
SIC Code 3841

Key Executives

Name Position
Steven M. Shum Chief Executive Officer and Director
Dr. Daniel Gedeon Teper MBA, PharmD President and Director
Andrea Goren Chief Financial Officer
Anna Baran-Djokovic J.D. Senior Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Apr 18, 2025 8-K Current Report
Apr 14, 2025 8-K Current Report
Mar 31, 2025 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 31, 2025 8-K Current Report
Mar 24, 2025 8-K Current Report
Mar 12, 2025 DEFR14A Filing
Mar 7, 2025 8-K Current Report
Feb 25, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 13, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Feb 11, 2025 DEF 14A Other definitive proxy statements